Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorSeoul National University Bundang Hospital
About this trial
The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.
Eligibility criteria
Qualifiers
Adults aged 20 years or older
Emergency department visit/hospitalization for acute heart failure with clinical evidence of congestion
Planned contrast-enhanced computed tomography during the index hospitalization
Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL/min/1.73 m²
Disqualifiers
Requirement for vasopressor therapy
Requirement for renal replacement therapy (dialysis)
Known allergy or hypersensitivity to furosemide
Ongoing acute coronary syndrome
Trial design
Treatments tested in this trial
- Furosemide
- 0.9 % Normal Saline
Treatment groups
190 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov